Medicus Pharma (MDCX) Institutional Ownership $2.18 -0.15 (-6.44%) As of 08/7/2025 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Medicus Pharma (NASDAQ:MDCX)Number ofInstitutional Buyers(last 12 months)6TotalInstitutional Inflows(last 12 months)$9.70MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$224.25K Get MDCX Insider Trade Alerts Want to know when executives and insiders are buying or selling Medicus Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data MDCX Institutional Buying and Selling by Quarter Medicus Pharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/1/2025 May Hill Capital LLC35,622$107K0.0%N/A0.262% 7/31/2025 Interchange Capital Partners LLC1,586,871$4.75M1.1%-4.5%11.694% 7/17/2025 Guyasuta Investment Advisors Inc.76,911$230K0.0%N/A0.567% 7/11/2025 SeaCrest Wealth Management LLC46,624$139K0.0%N/A0.344% 5/15/2025Armistice Capital LLC1,266,000$4.71M0.1%N/A9.427% 5/5/2025Private Advisor Group LLC56,750$211K0.0%N/A0.423% 4/30/2025 Interchange Capital Partners LLC1,661,871$6.18M1.7%+14.0%12.388% 2/11/2025 Interchange Capital Partners LLC1,457,165$3.63M1.3%N/A13.434% (Data available from 1/1/2016 forward) MDCX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of MDCX shares? During the previous two years, the following institutional investors and hedge funds held shares of Medicus Pharma shares: Interchange Capital Partners LLC ($4.75M), Armistice Capital LLC ($4.71M), Guyasuta Investment Advisors Inc. ($230K), Private Advisor Group LLC ($211K), and SeaCrest Wealth Management LLC ($139K), May Hill Capital LLC ($107K).Learn more on Medicus Pharma's institutional investors. Which institutional investors have been buying Medicus Pharma's stock? The following institutional investors have purchased Medicus Pharma's stock in the last 24 months: Interchange Capital Partners LLC ($1.66M), Armistice Capital LLC ($1.27M), Guyasuta Investment Advisors Inc. ($76.91K), Private Advisor Group LLC ($56.75K), SeaCrest Wealth Management LLC ($46.62K), and May Hill Capital LLC ($35.62K). How much institutional buying is happening at Medicus Pharma? Institutional investors have bought a total of 3,143,778 shares in the last 24 months. This purchase volume represents approximately $9.70M in transactions. Which of Medicus Pharma's major shareholders have been selling company stock? The following institutional investors have sold Medicus Pharma stock in the last 24 months: Interchange Capital Partners LLC ($75K). How much institutional selling is happening at Medicus Pharma? Institutional investors have sold a total of 75,000 shares in the last 24 months. This volume of shares sold represents approximately $224.25K in transactions. Related Companies Fate Therapeutics Major Shareholders Immuneering Major Shareholders Compugen Major Shareholders Natural Alternatives International Major Shareholders Protara Therapeutics Major Shareholders Seres Therapeutics Major Shareholders Spero Therapeutics Major Shareholders Inhibikase Therapeutics Major Shareholders BioHarvest Sciences Major Shareholders Protalix BioTherapeutics Major Shareholders This page (NASDAQ:MDCX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
